Synthesis, Preclinical Evaluation, and Clinical Application of the FAPI‐Dimer Based on the LARM Platform
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71798 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Fan Jia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of PET/CT-MR, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin, Heilongj…. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Membrane Proteins. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Project of Harbin Medical University Cancer Hospital Climbing Funding, Distinguished Young Scientist Funding of Harbin Medical University Affiliated Tumor Hospital.
Abstract (Originalsprache)
Fibroblast activation protein (FAP) is a promising pan‐tumor target for theranostics, but current FAP‐targeted radioligands are limited by insufficient tumor retention and suboptimal therapeutic doses. To address these challenges, we developed a novel LARM platform and synthesized the FAPI dimer TH2103‐100. The radiochemical labeling efficiency of TH2103‐100 with 68 Ga was nearly 100% at room temperature (radio‐TLC), significantly surpassing that of FAPI‐04 (35.28% at room temperature and 79% at 95°C). The radiochemical purity of 68 Ga‐TH2103‐100 was >97%. In vitro experiments demonstrated that 68 Ga‐TH2103‐100 exhibited superior cellular uptake and enhanced binding affinity. In vivo experiments showed that, compared with FAPI‐04, tumor uptake was increased by 3.9‐fold with prolonged retention and no significant toxicity. In healthy volunteers, the effective dose was 3.69E‐02 mSv/MBq. Preliminary clinical studies showed that 68 Ga‐TH2103‐100 exhibited promising diagnostic performance compared to 18 F‐FDG. The LARM‐based 68 Ga‐TH2103‐100 enables efficient room‐temperature labeling and superior tumor targeting, providing complementary diagnostic value for cases with inconclusive 18 F‐FDG PET/CT findings and offering a new paradigm for next‐generation FAP‐targeted molecular imaging agents, while its potential as an adjunct to 18 F‐FDG warrants further validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of PET/CT-MR, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
- School of Chemical Engineering and Technology, TianJin University, Tianjin, China.
- Theranosta New Drug Research and Development Co., Ltd, Jiangsu, China.
ORCID-Profile: Fan Jia, Dayong Hou, Kezheng Wang
Förderung
- National Natural Science Foundation of China
- Key Project of Harbin Medical University Cancer Hospital Climbing Funding
- Distinguished Young Scientist Funding of Harbin Medical University Affiliated Tumor Hospital
- Hong Kong Scholar Project
- Heilongjiang Provincial Natural Science Foundation of China
- Harbin Medical University Cancer Hospital Haiyan Foundation
- Key Innovation Technology Project Harbin Medical University Cancer Hospital Innovation Technology Funding
Zitieren
APA
Jia, F., You, H., Li, X., Cheng, L., Liu, W., Zhao, Y., Yang, X., Hu, G., Wang, Z., Hou, D., & Wang, K. (2026). Synthesis, Preclinical Evaluation, and Clinical Application of the FAPI‐Dimer Based on the LARM Platform. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71798
Vancouver
Jia F, You H, Li X, Cheng L, Liu W, Zhao Y, et al. Synthesis, Preclinical Evaluation, and Clinical Application of the FAPI‐Dimer Based on the LARM Platform. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71798
BibTeX
@article{Jia2026,
author = {Jia, Fan and You, Huihui and Li, Xinping and Cheng, Liang and Liu, Wei and Zhao, Yue and Yang, Xinyue and Hu, Geng and Wang, Zhi and Hou, Dayong and Wang, Kezheng},
title = {Synthesis, Preclinical Evaluation, and Clinical Application of the FAPI‐Dimer Based on the LARM Platform},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71798}
}
EUVIMED